Factors associated with the failure of clopidogrel dose-adjustment according to platelet reactivity monitoring to optimize P2Y12-ADP receptor blockade

Thrombosis Research

Volumn 130, Issue 1, 2012, Pages 70-74

  Bonello, Laurent ^a   Camoin Jau, Laurence ^b,c   Mancini, Julien ^d,e   Bessereau, Jacques ^d   Grosdidier, Charlotte ^e   Alessi, Marie Christine ^e   Ostorero, Michel ^f   Dignat George, Françoise ^b,c   Paganelli, Franck ^a  

^a HÔPITAL NORD   (France)

^b INSERM   (France)

^c HÔPITAL DE LA CONCEPTION   (France)

^d TIMONE HOSPITAL   (France)

^e AIX MARSEILLE UNIVERSITY   (France)

^f Hopital de Martigues   (France)

Author keywords

Acute coronary syndrome; genetic polymorphism; high on treatment platelet reactivity; P2Y12 ADP receptor; vasodilator stimulated phosphoprotein

Indexed keywords

ACETYLSALICYLIC ACID; ARYLDIALKYLPHOSPHATASE 1; CALCIUM CHANNEL BLOCKING AGENT; CLOPIDOGREL; CYTOCHROME P450 2C19; MULTIDRUG RESISTANCE PROTEIN 1; OMEPRAZOLE; PURINERGIC P2Y12 RECEPTOR;

ADULT; AGED; ALLELE; ARTICLE; CLINICAL ASSESSMENT TOOL; DRUG HYPERSENSITIVITY; FEMALE; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NON ST SEGMENT ELEVATION ACUTE CORONARY SYNDROME; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; RECEPTOR BLOCKING; THROMBOCYTE ACTIVATION; TREATMENT FAILURE;

ACUTE CORONARY SYNDROME; AGED; ARYL HYDROCARBON HYDROXYLASES; ARYLDIALKYLPHOSPHATASE; BLOOD PLATELETS; CELL ADHESION MOLECULES; DRUG DOSAGE CALCULATIONS; FEMALE; HUMANS; MALE; MICROFILAMENT PROTEINS; MIDDLE AGED; P-GLYCOPROTEIN; PHOSPHOPROTEINS; PLATELET AGGREGATION INHIBITORS; POLYMORPHISM, GENETIC; PURINERGIC P2Y RECEPTOR ANTAGONISTS; RECEPTORS, PURINERGIC P2; RECEPTORS, PURINERGIC P2Y12; TICLOPIDINE;

EID: 84861832413     PISSN: 00493848     EISSN: 18792472     Source Type: Journal    
DOI: 10.1016/j.thromres.2011.12.038     Document Type: Article

References (27)

1. CURE Investigators Clopidogrel in Unstable angina to prevent Recurrent Events trial Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study Lancet 358 2001 527 533
2. G. Hollopeter, H.M. Jantzen, D. Vincent, G. Li, L. England, and V. Ramakrishnan Identification of platelet ADP receptor targeted by antithrombotic drugs Nature 409 2001 202 207
3. L. Bonello, U.S. Tantry, R. Marcucci, R. Blindt, D.J. Angiolillo, and R. Becker Consensus and Future Directions on the Definition of High On-Treatment Platelet Reactivity to ADP J Am Coll Cardiol 56 2010 919 933
4. D.J. Angiolillo, A. Fernandez-Ortiz, E. Bernardo, F. Alfonso, C. Macaya, and T.A. Bass Variability in individual responsiveness to clopidogrel: clinical implications, management, and future perspectives J Am Coll Cardiol 49 2007 1505 1516
5. T. Simon, C. Verstuyft, M. Mary-Krause, L. Quteineh, E. Drouet, and N. Méneveau Genetic Determinants of Response to Clopidogrel and Cardiovascular Events N Engl J Med 360 2009 363 375
6. H.J. Bouman, E. Schömig, J.W. van Werkum, J. Velder, C.M. Hackeng, and C. Hirschhäuser Paraoxonase-1 is a major determinant of clopidogrel efficacy Nat Med 17 2011 110 116
7. J.L. Mega, S.L. Close, S.D. Wiviott, L. Shen, J.R. Walker, and T. Simon Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON-TIMI 38 trial: a pharmacogenetic analysis Lancet 376 2010 1312 1319
8. L. Bonello, L. Camoin-Jau, S. Arques, C. Boyer, D. Panagides, and O. Wittenberg Adjusted clopidogrel loading doses according to vasodilator- stimulated phosphoprotein phosphorylation index decrease rate of major adverse cardiovascular events in patients with clopidogrel resistance: A multicenter randomized prospective study J Am Coll Cardiol 51 2008 1404 1411
9. L. Bonello, L. Camoin-Jau, S. Armero, O. Com, S. Arques, and C. Burignat-Bonello Tailored clopidogrel loading dose according to platelet reactivity monitoring to prevent acute and subacute stent thrombosis Am J Cardiol 103 2009 5 10
10. L. Bonello, M. Pansieri, J. Mancini, R. Bonello, L. Maillard, and P. Barnay High on-treatment platelet reactivity after prasugrel loading dose and cardiovascular events after percutaneous coronary intervention in acute coronary syndromes J Am Coll Cardiol 58 2011 467 473
11. TRITON-TIMI 38 Investigators Prasugrel versus clopidogrel in patients with acute coronary syndromes N Engl J Med 357 2007 2001 2015
12. N. Bonello-Palot, S. Armero, F. Paganelli, J. Mancini, A. De Labriolle, and C. Bonello Relation of body mass index to high on-treatment platelet reactivity and of failed clopidogrel dose adjustment according to platelet reactivity monitoring in patients undergoing percutaneous coronary intervention Am J Cardiol 104 2009 1511 1515
13. J.S. Hulot, A. Bura, E. Villard, M. Azizi, V. Remones, and C. Goyenvalle Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects Blood 108 2006 2244 2247
14. J.P. Collet, J.S. Hulot, A. Pena, E. Villard, J.B. Esteve, and J. Silvain Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study Lancet 373 2009 309 317
15. J.L. Mega, S.L. Close, S.D. Wiviott, L. Shen, R.D. Hockett, and J.T. Brandt Cytochrome p-450 polymorphisms and response to clopidogrel N Engl J Med 360 2009 354 362
16. A.R. Shuldiner, J.R. O'Connell, K.P. Bliden, A. Gandhi, K. Ryan, and R.B. Horenstein Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy JAMA 302 2009 849 857
17. French Registry of Acute ST-Elevation and Non-ST-Elevation Myocardial Infarction (FAST-MI) Investigators Genetic determinants of response to clopidogrel and cardiovascular events N Engl J Med 360 2009 363 375
18. L. Bonello, S. Armero, O. Ait Mokhtar, J. Mancini, P. Aldebert, and N. Saut Clopidogrel loading dose adjustment according to platelet reactivity monitoring in patients carrying the 2C19*2 loss of function polymorphism J Am Coll Cardiol 56 2010 1630 1636
19. D. Sibbing, W. Koch, S. Massberg, R.A. Byrne, J. Mehilli, and S. Schulz No association of paraoxonase-1 Q192R genotypes with platelet response to clopidogrel and risk of stent thrombosis after coronary stenting Eur Heart J 32 2011 1605 1613
20. T. Simon, P.G. Steg, L. Becquemont, C. Verstuyft, S. Kotti, and F. Schiele Effect of paraoxonase-1 polymorphism on clinical outcomes in patients treated with clopidogrel after an acute myocardial infarction Clin Pharmacol Ther 90 2011 561 567
21. C. Kimchi-Sarfaty, J.M. Oh, I.W. Kim, Z.E. Sauna, A.M. Calcagno, and S.V. Ambudkar A "silent" polymorphism in the MDR1 gene changes substrate specificity Science 315 2007 525 528
22. D. Taubert, N. von Beckerath, G. Grimberg, A. Lazar, N. Jung, and T. Goeser Impact of P-glycoprotein on clopidogrel absorption Clin Pharmacol Ther 80 2006 486 501
23. C. Verstuyft, M. Schwab, E. Schaeffeler, R. Kerb, U. Brinkmann, and P. Jaillon Digoxin pharmacokinetics and MDR1 genetic polymorphisms Eur J Clin Pharmacol 58 2003 809 812
24. J.L. Mega, S.L. Close, S.D. Wiviott, L. Shen, R.D. Hockett, and J.T. Brandt Cytochrome P450 genetic polymorphisms and the response to prasugrel: relationship to pharmacokinetic, pharmacodynamic, and clinical outcomes Circulation 119 2009 2553 2560
25. M.M. Ameyaw, F. Regateiro, T. Li, X. Liu, M. Tariq, and A. Mobarek MDR1 pharmacogenetics: frequency of the C3435T mutation in exon 26 is significantly influenced by ethnicity Pharmacogenetics 11 2001 217 221
26. N. von Beckerath, D. Taubert, G. Pogatsa-Murray, E. Schömig, A. Kastrati, and A. Schömig Absorption, metabolization, and antiplatelet effects of 300-, 600-, and 900-mg loading doses of clopidogrel: results of the ISAR-CHOICE (Intracoronary Stenting and Antithrombotic Regimen: Choose Between 3 High Oral Doses for Immediate Clopidogrel Effect) Trial Circulation 112 2005 2946 2950
27. PLATO investigators Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic sub-study of the PLATO trial Lancet 376 2010 1320 1328